These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19236228)

  • 21. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M; Zhang D; Zhang H; Shyu WC
    Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gauging reactive metabolites in drug-induced toxicity.
    Eno MR; Cameron MD
    Curr Med Chem; 2015; 22(4):465-89. PubMed ID: 25174933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NMR Based Metabolomics: An Exquisite and Facile Method for Evaluating Therapeutic Efficacy and Screening Drug Toxicity.
    Guleria A; Kumar A; Kumar U; Raj R; Kumar D
    Curr Top Med Chem; 2018; 18(20):1827-1849. PubMed ID: 30465509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical approaches to resolving reactive metabolite liabilities in early discovery.
    Dalvie D; Kalgutkar AS; Chen W
    Drug Metab Rev; 2015 Feb; 47(1):56-70. PubMed ID: 25410913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs in control samples in nonclinical safety studies: a reconsideration.
    Zimmer D
    Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
    [No Abstract]   [Full Text] [Related]  

  • 27. New analytical strategies in studying drug metabolism.
    Staack RF; Hopfgartner G
    Anal Bioanal Chem; 2007 Aug; 388(7):1365-80. PubMed ID: 17583803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High resolution mass spectrometry-based methodologies for identification of Etravirine bioactivation to reactive metabolites: In vitro and in vivo approaches.
    Godinho ALA; Martins IL; Nunes J; Charneira C; Grilo J; Silva DM; Pereira SA; Soto K; Oliveira MC; Marques MM; Jacob CC; Antunes AMM
    Eur J Pharm Sci; 2018 Jul; 119():70-82. PubMed ID: 29592839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive listing of bioactivation pathways of organic functional groups.
    Kalgutkar AS; Gardner I; Obach RS; Shaffer CL; Callegari E; Henne KR; Mutlib AE; Dalvie DK; Lee JS; Nakai Y; O'Donnell JP; Boer J; Harriman SP
    Curr Drug Metab; 2005 Jun; 6(3):161-225. PubMed ID: 15975040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Importance of Bioactivation in Computer-Guided Drug Repositioning. Why the Parent Drug is Not Always Enough.
    Talevi A
    Curr Top Med Chem; 2016; 16(19):2078-87. PubMed ID: 26881710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
    Baillie TA
    Chem Res Toxicol; 2009 Feb; 22(2):263-6. PubMed ID: 19216579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idiosyncratic toxicity: the role of toxicophores and bioactivation.
    Williams DP; Park BK
    Drug Discov Today; 2003 Nov; 8(22):1044-50. PubMed ID: 14690635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic activation in drug-induced liver injury.
    Leung L; Kalgutkar AS; Obach RS
    Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
    Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry.
    Ma S; Subramanian R
    J Mass Spectrom; 2006 Sep; 41(9):1121-39. PubMed ID: 16967439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
    Kalgutkar AS; Didiuk MT
    Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening and identification of GSH-trapped reactive metabolites using hybrid triple quadruple linear ion trap mass spectrometry.
    Zheng J; Ma L; Xin B; Olah T; Humphreys WG; Zhu M
    Chem Res Toxicol; 2007 May; 20(5):757-66. PubMed ID: 17402749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicology Strategies for Drug Discovery: Present and Future.
    Blomme EA; Will Y
    Chem Res Toxicol; 2016 Apr; 29(4):473-504. PubMed ID: 26588328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies and chemical design approaches to reduce the potential for formation of reactive metabolic species.
    Argikar UA; Mangold JB; Harriman SP
    Curr Top Med Chem; 2011; 11(4):419-49. PubMed ID: 21320068
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.